These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big TechMarket Watch • 09/22/25
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the BillThe Motley Fool • 09/20/25
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimenPRNewsWire • 09/19/25
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myelomaPRNewsWire • 09/19/25
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)GlobeNewsWire • 09/19/25
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's WhyZacks Investment Research • 09/18/25
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasisPRNewsWire • 09/17/25
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual MeetingPRNewsWire • 09/15/25
If You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 09/15/25
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report saysMarket Watch • 09/12/25
J&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in WaterlooAccesswire • 09/12/25
Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigmGlobeNewsWire • 09/11/25
Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline MomentumZacks Investment Research • 09/10/25